The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible financial incentives from the Singapore government. London-listed AstraZeneca has been expanding into markets like China, Indonesia and India over the past few years in an effort to widen its supply chain.